Abstracts
Copyright ©The Author(s) 2000. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 15, 2000; 6(Suppl3): 89-89
Published online Sep 15, 2000. doi: 10.3748/wjg.v6.iSuppl3.89
Immunohistochemical study on p53, H-rasp21, c-erbB-2 protein and proliferating cell nuclear antigen expression in tumor tissues of Han and minority ethnic patients with primary hepatic carcinoma in Xinjiang
Guo-Yue Lin, Zhao-Lun Chen, Cai-Mo Lu, Yin Li, Jun Wang, Xiao-Jia Ping, Rong Huang
Guo-Yue Lin, Cai-Mo Lu, Jun Wang, No. 474 Hospital of PLA, Urumqi 830011, Xinjiang Uygur Autonomic Region, China
Zhao-Lun Chen, Yin Li, Xiao-Jia Ping, Rong Huang, Department of Pathology, the 1st Teaching Hospital, Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomic Region, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Zhao-Lun Chen, Professor, Department of Pathology, the 1st Teaching Hospital, Xinjiang Medical University, and Dr. Guo-Yue Lin, No. 474 Hospital of PLA, Urumqi 830011, China
Telephone: 991-6625448-2276/2290 Fax: 991-3836386
Received: April 3, 2000
Revised: April 20, 2000
Accepted: May 18, 2000
Published online: September 15, 2000
Abstract

AIM: To find out if there is any difference in human primary liver carcinogenesis between Han and minority ethnic patients in Xinjiang.

METHODS: Expression of p53, c-erbB-2, H-rasp21 protein and proliferating cell nuclear antigen (PCNA) in tumor tissues of 50 patients (Han 38, minorities 12) with primary hepatic carcinoma (HCC) was detected by immunohistochemistry (LSAB).

RESULTS: The positive frequency of p53, c-erbB-2, H-rasp21 and PCNA expression was 46.0% (23/50, 70.0% (35/50), 68.0% (34/50) and 82.0% (41/50) in tumor tissues; 4.0% (2/50), 22.0% (11/50), 64.0% (32/50) and 52.0% (26/50) in peritumor respectively with a significant difference, except for H-rasp21 (P < 0.05) between tumor and non-tumor tissues. Combined the three oncogenes alteration, 26% (13/50) tumor tissues had positive immunoreactivity, but peritumor and normal liver were negative. The positive p53, c-erbB-2, H-rasp21 protein expression was 39.5% (15/38), 60.5% (23/38) and 39.5% (15/38) in tumors of Han patients; 66.7% (8/12), 100% (12/12) and 75.0% (9/12) in minority patients respectively. A statistical difference between Han and minority cancer samples was observed (P < 0.05).

CONCLUSION: Overexpression of p53, c-erbB-2 and H-rasp21 in human primary liver carcinoma is an important biomarker of genetic alteration. The different frequency of these oncogenetic changes may reflect some environmental factors or/and ethnic hereditary affecting the liver carcinogenesis. The special life style of Han, Uygur, Kazak and Mongolia nationalities in Xinjiang may also involve the etiopathogenesis of this disease.

Keywords: Liver neoplasms/etiology; Oncogenes; X nationality; Environment; Genes, p53; Immunohistochemistry